Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.85 |
| ▸ | MEN1 | O00255 | 6/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.85 |
| ▸ | LMNA | P02545 | 6/20 | 0.85 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.85 |
| ▸ | TUBB | P07437 | 5/20 | 0.85 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.85 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.85 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.85 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.85 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.85 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.85 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.85 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.85 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.85 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.85 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.85 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.85 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Roseamine SCHEMBL10059227 | 1.00 | MAPT (0.85) | MAPTMEN1KMT2ALMNATUBB4A | |
| SCHEMBL15941262 | 0.95 | TUBB4A (0.79) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinepidine SCHEMBL285304 | 0.94 | LMNA (0.85) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinepidine SCHEMBL29385187 | 0.94 | LMNA (0.85) | MAPTMEN1KMT2ALMNATUBB4A | |
| SCHEMBL12213867 | 0.93 | MAPT (0.83) | MAPTMEN1KMT2ALMNATUBB4A | |
| SCHEMBL12237564 | 0.93 | MAPT (0.83) | MAPTMEN1KMT2ALMNATUBB4A | |
| SCHEMBL10018533 | 0.93 | MAPT (0.83) | MAPTMEN1KMT2ALMNATUBB4A | |
| SCHEMBL12451436 | 0.93 | MAPT (0.73) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinepidine SCHEMBL29376135 | 0.93 | MAPT (0.85) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinepidine SCHEMBL4076 | 0.93 | MAPT (0.85) | MAPTMEN1KMT2ALMNATUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262706-A1 | SITE-SPECIFIC PROTEIN LABELING USING OLIGONUCLEOTIDE TAGS | INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED (IN) | 2025-12-26 | — | — | WO | claimed |
| CN-116083974-A | Cobalt plating additive, cobalt plating solution and method suitable for filling cobalt into microelectronic circuit | 哈尔滨工业大学 | 2023-05-09 | — | — | CN | claimed |
| EP-4709877-A2 | METHODS AND KITS FOR DETECTING ENDOTOXIN | Life Technologies Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260056217-A1 | NORMALIZATION METHODS | LIFE TECHNOLOGIES CORP (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4695308-A1 | ENGINEERED ANTIBODIES AND USES THEREOF | Invitrogen BioServices India Private Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025262706-A1 | SITE-SPECIFIC PROTEIN LABELING USING OLIGONUCLEOTIDE TAGS | INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED (IN) | 2025-12-26 | — | — | WO | disclosed |
| EP-4594735-A2 | NORMALIZATION METHODS | Life Technologies Corporation (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025090132-A9 | METHODS AND KITS FOR DETECTING ENDOTOXIN | LIFE TECHNOLOHGIES CORPORATION (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025090132-A2 | METHODS AND KITS FOR DETECTING ENDOTOXIN | LIFE TECHNOLOHGIES CORPORATION (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-119744346-A | Normalization method | 生命技术公司 | 2025-04-01 | — | — | CN | disclosed |
| WO-2025057225-A1 | ENGINEERED ANTIBODIES AND USES THEREOF | INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED (IN) | 2025-03-20 | — | — | WO | disclosed |
| WO-2024238249-A1 | EXTRACELLULAR VESICLE PROTEIN AND NUCLEIC ACID ANALYSIS | Life Technologies Corporation (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-112279864-B | Difunctional coumarin oxime ester compound and preparation and application thereof | 湖北固润科技股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2024073291-A2 | NORMALIZATION METHODS | Life Technologies Corporation (US) | 2024-04-04 | — | — | WO | disclosed |
| CN-115583931-B | Ether-functionalized coumarin oxime ester compound and preparation and application thereof | 湖北固润科技股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260056217-A1 | NORMALIZATION METHODS | KCNQ5, KCNQ4, KCNQ2 | MAPT 2356/4885MEN1 1008/4885KMT2A 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.